L'étude des types de la mort cellulaire et les stades de l'apoptose des leucocytes chez les patients atteints de la tuberculose pulmonaire aux différents programmes de traitement antimycobactérien L'objectif. D'évaluer l'état des membranes cytoplasmiques des leucocytes et étudier leur viabilité, déterminer les variétés et les stades de la mort cellulaire des leucocytes chez des patients avec tuberculose pulmonaire traités par différents schémas de traitement antimycobactérien. Matériaux et méthodes. L'étude a été réalisée sur 30 patients atteints de tuberculose pulmonaire: 1er groupe-12 patients traités par un schéma thérapeutique standard avec des médicaments en ligne; 2-ème groupe-patients traités individuellement avec les médicaments de la gamme I et II. Le groupe témoin comprenait 12 donneurs en bonne santé. L'étude a été réalisée par la cytométrie en flux sur un cytomètre en

La dynamique des vitamines B1 et B12 en tant que prediction de neuropathie périphérique chez les patients atteints de tuberculose pulmonaire Le but de l'étude est de pronostiquer l'évolution de la neuropathie périphérique en étudiant la dynamique des taux de vitamines B1 et B12 chez les patients atteints d'une tuberculose pulmonaire nouvellement diagnostiquée lors d'un traitement par des antituberculeux de première et de deuxième ligne. Matériels et méthodes. L'étude portait sur 22 patients atteints de tuberculose sensible et recevant un schéma thérapeutique standard à 4 composants incluant de l'isoniazide et 26 patients atteints de tuberculose résistante aux médicaments dont le schéma thérapeutique comprenait du linézolide. Le groupe témoin-20 individus en bonne santé. Les taux plasmatiques de vitamines B1 et B12 ont été étudiés chez tous les patients avant le traitement et après 30 jours

No abstract

MODIFICATION OF CLINICAL COURSE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A MYTH OR ESSENTIAL REALITY OF PRESENT? Y. I. Feshchenko, M. M. Ostrovskiy, I. Y. Makoyda Abstract Chronic obstructive pulmonary disease (COPD) remains in the top chart of respiratory diseases affecting mankind, being the most prevalent pulmonary condition and one of major cause of death. Bronchial tree and alveolar structures remodeling, hyperproduction of phlegm, persisting inflammation, microcirculation disturbances, hypoxia, bad habits are the list of factors, leading (if left uncontrolled) to initiation or progression of COPD and development of its complications. Timely diagnostics and management of COPD aimed on preventing of a galloping progression of the disease, is a leading point of interest for healthcare practitioners. Modification of COPD clinical course is one of outcomes to be reached by a physician in cooperation with a patient. Use of original mucolytic erdosteine, which possesses pleiotropic effects, counteracts multiple pathological mechanisms. Breaking disulfide bonds of glycoproteins improves sputum viscosity and makes phlegm easier to cough up. Anti-oxidant effect is mediated by suppression of lipids peroxidation and alfa1-antitrypsin inactivation, as well as increasing of glutathione level in bronchoalveolar lavage fluid. Important effect is a suppression of pro-inflammatory cytokines synthesis (IL-6, IL-8) and modification of inflammation activity. Data from randomized clinical trial RESTORE have demonstrated the potency of erdosteine 300 mg twice daily taken 1 year as add-on to maintenance COPD therapy in terms of reduction of duration, rate and severity of exacerbations. DELFI clinical study (2020) has confirmed the confidence of leading chest physicians and hospitals of Europe in this molecule. Key words: chronic obstructive pulmonary disease, erdosteine, modification of course.

The aim: To study the structure of adverse drug reactions and the effectiveness of treatment among patients with drug-resistant tuberculosis who follow the modified short-term and individualized treatment regimens. Materials and methods: The analysis of 138 inpatient medical records, outpatient health cards and electronic database of the patient register was conducted. Resistant strains of MTB were microbiologically verified in all the patients. All the patients underwent clinical-laboratory, instrumental microbiological, genetic-molecular (GeneXpert MTB / RIF) methods of examination, both for diagnosis and monitoring of the effectiveness of treatment. In order to prevent complications and control adverse reactions, all the patients were briefly screened for peripheral neuropathy, basic audiometry, the QTc interval was determined, visual acuity and color perception were checked. Results: At individualized treatment regimen of tuberculosis, adverse reactions were 3.5 times more common than in patients with modified short-term therapy, in 65 (68.4%) cases and in 8 (18.6%) cases, respectively. Accordingly, the effectiveness of treatment differed in both groups. Prevailing in long-term treatment were: treatment interruption treatment gap, treatment failure, continued treatment. In patients receiving short-term regimens, the cured rate was almost twice as common as in the second group. Conclusions: Timely detection cases of resistant tuberculosis and using linear probe analysis (LPA) - GenoType MTBDRplus for diagnosis of fluoroquinolone resistance, will allow the use of modified short-term treatment regimens for tuberculosis. Which in turn will reduce the number of side effects and improve the outcome of treatment.